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Abstract
MicroRNAs (miRNAs) are a class of small, conserved, tissue-specific regulatory non-coding 
RNAs that modulate a variety of biological processes and play a fundamental role in pathogenesis 
of major human diseases, including nonalcoholic fatty liver disease (NAFLD). However, the 
association between inter-individual differences in susceptibility to NAFLD and altered miRNA 
expression is largely unknown. In view of this, the goals of the present study were (i) to determine 
whether or not individual differences in the extent of NAFLD-induced liver injury are associated 
with altered miRNA expression, and (ii) assess if circulating blood miRNAs may be used as 
potential biomarkers for the noninvasive evaluation of the severity of NAFLD. A panel of seven 
genetically diverse strains of inbred male mice (A/J, C57BL/6J, C3H/HeJ, 129S/SvImJ, CAST/
EiJ, PWK/PhJ, and WSB/EiJ) were fed a choline- and folate-deficient (CFD) diet for 12 weeks. 
This diet induced liver injury in all mouse strains; however, the extent of NAFLD-associated 
pathomorphological changes in the livers was strain-specific, with A/J, C57BL/6J, and C3H/HeJ 
mice being the least sensitive and WSB/EiJ mice being the most sensitive. The morphological 
changes in the livers were accompanied by differences in the levels of hepatic and plasma 
miRNAs. The levels of circulating miR-34a, miR-122, miR-181a, miR-192, and miR-200b 
miRNAs were significantly correlated with a severity of NAFLD-specific liver 
pathomorphological features, with the strongest correlation occurring with miR-34a. These 
observations suggest that the plasma levels of miRNAs may be used as biomarkers for 
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noninvasive monitoring the extent of NAFLD-associated liver injury and susceptibility to 
NAFLD.
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INTRODUCTION
The incidence of nonalcoholic fatty liver disease (NAFLD) is increasing dramatically in the 
United States and developed countries (Tiniakos et al., 2010; Bellentani et al., 2010). It is 
estimated that 25%–30% of adults in the United States have NAFLD (Pascale et al., 2010; 
Day, 2011) and that NAFLD accounts for 39% of newly diagnosed cases of chronic liver 
disease (Pascale et al., 2010). NAFLD is composed of several related liver disorders ranging 
from uncomplicated steatosis to non-alcoholic steatohepatitis (NASH). More importantly, 
NAFLD is considered to be a major risk factor for the development of other chronic liver 
diseases, such as fibrosis, cirrhosis, and hepatocellular carcinoma (Siegel and Zhu, 2009; 
Starley et al., 2010; Welzel et al., 2011). The underlying molecular mechanisms involved in 
the etiology and pathogenesis of NAFLD are only partially understood and pharmacotherapy 
options are limited (Cohen et al., 2011). Supportive treatment strategies for NAFLD are 
focused on managing the metabolic syndrome and chronic inflammation in the liver; thus, 
early detection of the disease is critical for improved prognosis and prevention of more 
serious liver illnesses. A recent report by Paie et al. in a small cohort of patients with 
NAFLD demonstrated that isolated steatosis does progress to NASH accompanied by a 
worsening of the metabolic syndrome (Pais et al., 2011), and suggested the crucial need for 
continued hepatic monitoring in patients diagnosed with uncomplicated NAFLD. 
Unfortunately, at the present time, a liver biopsy is the only method for the diagnosis and 
assessment of disease progression (Sanyal et al., 2011).
Even though the incidence of NAFLD in the general population is appreciable, it is 
estimated that only 10% of those diagnosed will progress to liver fibrosis or cirrhosis (Siegel 
and Zhu, 2009). In addition, the incidence of NAFLD varies greatly among racial groups 
(Browning et al., 2004) and NAFLD is a highly heritable trait (Schwimmer et al., 2011). A 
recent genome-wide association study (GWAS) of the subjects with histopathologicaly-
confirmed NAFLD identified several single nucleotide polymorphisms as potential genetic 
modifiers of the NAFLD activity score, fibrosis, inflammation, and serum alanine 
aminotransferase (ALT) levels (Chalasani et al., 2010). Because the pathogenesis of 
NAFLD is complex and involves dysregulation of several interdependent physiological 
processes, including lipid metabolism, insulin resistance, immune response, inflamation, 
oxidative stress, and apoptosis (Marra et al., 2008; Larter et al., 2010), additional studies in 
human populations or animal models of the human population (Rusyn et al., 2010) are 
needed to elucidate the genetic determinants of NAFLD.
Investigating the molecular basis of how genetic factors influence the susceptibility to 
NAFLD in humans is frequently impractical and always very complex, whereas using 
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relevant animal models may substantially overcome many limitations of human-only 
studies. Several studies have demonstrated an inter-strain variability in the susceptibility of 
mice to NAFLD, NASH, and hepatocarcinogenesis induced by either high-fat diet, or 
methionine- and choline-deficient diet (Yamazaki et al., 2008; Hill-Baskin et al., 2009). 
Each of these dietary models has some advantages and limitations. For instance, feeding 
high-energy diets compromises the metabolic status and induces obesity but does not 
uniformly cause liver injury (Maher, 2011). In contrast, feeding either a methionine- and 
choline-deficient or choline-deficient diet to rats or mice causes liver injury similar to 
NAFLD but does not attain the compromised metabolic status observed in patients.
Previous reports have convincingly demonstrated that dysregulation of miRNA expression is 
an important early event in the pathogenesis of NAFLD in humans (Cheung et al., 2008) and 
mice (Wang et al., 2009a). However, the association between inter-individual differences in 
susceptibility to NAFLD and altered miRNA expression is largely unknown.
To explore further the potential mechanisms of inter-individual differences in susceptibility 
and severity of NAFLD-related liver injury, we fed a panel of seven genetically diverse 
inbred mouse strains that are parental lines in the Collaborative Cross (Aylor et al., 2011) 
the choline- and folate-deficient (CFD) diet that consistently induces fat-related liver injury 
resembling pathomorphological features of human NAFLD (Maher, 2011). We determined 
the inter-strain variability in severity of NAFLD induced by the CFD diet and its association 
with aberrations in miRNA expression. We also assessed whether or not circulating blood 
miRNAs may be used as potential biomarkers for noninvasive evaluation of liver injury in 
NAFLD. Because miRNA expression in mouse liver varies little among inbred strains (Gatti 
et al., 2011) the establishment of circulatory miRNA biomarkers as noninvasive diagnostics 
of the severity of NAFLD may fill a critical gap in clinical practice.
MATERIALS AND METHODS
Animals and experimental design
Male A/J, C57BL/6J, C3H/HeJ, 129S1/SvImJ, CAST/EiJ, PWK/PhJ, and WSB/EiJ mice (6 
weeks of age) were obtained from the Jackson Laboratory (Bar Harbor, ME). These strains 
were selected because they provide an excellent representation of the broad genetic diversity 
and their genomes have been fully sequenced (Yang et al., 2011). The mice were housed in 
sterilized cages in a temperature-controlled room (24°C) with a 12 h light/dark cycle, and 
given ad libitum access to purified water and NIH-31 pelleted diet. At 8 weeks of age, mice 
from each strain were allocated randomly into control and experimental groups. Mice in the 
experimental groups were maintained on the CFD diet, a diet lacking choline and folic acid 
(Diet #519541, choline and folate deficient, iron supplemented, and L-amino acid defined 
diet; Dyets, Inc., Bethlehem, PA) for 12 weeks. Mice in the control groups received the 
same diet supplemented with 0.4% methionine, 0.3% choline bitartrate, and 2 mg/kg folic 
acid. Diets were stored at 4°C before use and given ad libitum with replacement twice a 
week. Body weights of the mice were recorded weekly. Five experimental and five control 
mice from each strain were euthanized by exsanguination following deep isoflurane 
anesthesia 12 weeks after diet initiation. Blood was collected into BD vacutainer EDTA 
containing blood collection tubes (BD Biosciences, Franklin Lakes, NJ) by direct puncture 
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of the heart. Plasma was isolated by centrifugation at 3,000 rpm for 10 minutes at 4°C 
according to the manufacturer’s instructions and stored at −80°C. The livers were excised 
and a slice of the median lobe was fixed in neutral buffered formalin for 48 h for 
histopathological examination. The remaining liver was snap-frozen immediately in liquid 
nitrogen and stored at −80°C for subsequent analyses. All experimental procedures were 
reviewed and approved by the National Center for Toxicological Research Animal Care and 
Use Committee.
Biochemical analyses
Serum triglyceride, ALT, aspartate aminotransferase (AST), lactate dehydrogenase (LDH), 
total cholesterol, and glucose levels were measured using an ACE Alera® Clinical 
Chemistry System (Alfa Wassermann Inc., West Caldwell, NJ) according to the 
manufacturer’s protocol.
Tissue processing, histological analysis and criteria for pathology assessment
After 48 h, a slice of the median lobe of the liver that was fixed in 10% neutral buffered 
formalin was trimmed, processed, and embedded in infiltrating media (Surgipath Formula 
R®, Leica Biosystems, Richmond, IL), sectioned at approximately 5 microns, mounted on a 
glass slide, and stained with hematoxylin and eosin. The liver sections were examined 
histopathologically for NAFLD-specific lesions, including cytoplasmic alteration, steatosis, 
hepatocellular degeneration, inflammation, hepatocellular karyocytomegaly, and oval cell 
proliferation, and graded using a severity score system for each of the morphological 
parameters as follows: grade 0, absent; grade 1, minimal; grade 2, mild; grade 3, moderate; 
and grade 4, severe changes. Total liver pathology scores were calculated as the mean 
severity for all of the NAFLD-specific lesions detected in the livers of the mouse strains.
RNA extraction and miRNA expression analysis by quantitative reverse transcription real-
time PCR (qRT-PCR)
Total RNA was extracted from liver tissue using miRNAeasy Mini kits (Qiagen, Valencia, 
CA) according to the manufacturer’s instructions. Total RNA (100 ng) was used for qRT-
PCRs of miR-122, miR-192, miR-34a, miR-200b, miR-221, and miR-181a using TaqMan 
miRNA assays (Applied Biosystems, Foster City, CA), according to the manufacturer’s 
instructions. SnoRNA202 was used as an endogenous control. The relative amount of each 
miRNA was measured using the 2−ΔΔCt method (Schmittgen and Livak, 2008). All qRT-
PCR reactions were conducted in triplicate and repeated twice.
Total plasma RNA, including miRNA, was isolated using QIAzol reagent (Qiagen) 
according to the manufacturer’s instructions with minor modifications. In brief, 700 μl of 
QIAzol reagent containing 1.2 μg of carrier MS2 RNA (Roche Diagnostics Corporation, 
Indianapolis, IN) was added to 100 μl of each plasma sample. The sample was mixed in a 
tube, spiked with 4 μl of 0.5 μM cel-miR-54 miRNA (Qiagen), and 140 μl of chloroform 
was added. After mixing vigorously for 15 s, the sample was then centrifuged at 12,000 g 
for 15 min. The upper aqueous phase was carefully transferred to a new collection tube, and 
precipitated with 2 volumes of isopropanol, centrifuged at 18,000 g for 15 min, and washed 
with 75 % ethanol. After air drying, the RNA was dissolved in 30 μl RNase-free water. The 
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quality and quantity of the RNA was evaluated using a NanoDrop 200c spectrophotometer 
(Thermo Fisher Scientific, Waltham, MA). The efficiency of small RNA isolation was 
monitored by determining the amount of spiked miRNA recovered by using TaqMan 
miRNA assays (Applied Biosystems). Total RNA (1.5 μl per reaction) was used for qRT-
PCRs of miR-122, miR-34a, miR-200b, miR-192, miR-221, and miR-181a using TaqMan 
miRNA assays (Applied Biosystems), according to the manufacturer’s instructions. The 
relative amount of each miRNA was measured using the 2−ΔΔCt method and normalized to 
mmu-miR-16, a ubiquitous non-liver-specific miRNA.
Statistical analyses
Results are presented as mean ± S.D. Clinical chemistry values, body weights, and miRNA 
levels were analyzed by two-way analysis of variance (ANOVA), with pair-wise 
comparisons being made by the Student-Newman-Keuls method. When necessary, the data 
were natural log transformed before conducting the analyses to maintain a more equal 
variance or normal data distribution. Histopathology scores were evaluated by one-way 
ANOVA, using strain as the fixed factor. Pearson product-moment correlation coefficients 
were used to determine the relationship between miRNA levels and histopathology scores. 
P-values <0.05 were considered significant.
RESULTS
Inter-strain differences in liver pathology elicited by a choline- and folate-deficient diet
Over the course of this 12 week study, all mice fed the CFD diet gained weight, with the 
129S1/SvImJ mice gaining significantly more than the methyl-sufficient control mice, and 
the WSB/EiJ mice gaining significantly less than the methyl-sufficient control mice (Table 
1). These results are in contrast to some of the previous reports that found a substantial loss 
of the body weight, often between 20–40%, as a result of feeding mice various formulations 
of “lipogenic methyl-deficient diets”, e.g., methionine- and choline-deficient, or choline-
deficient diets (Larter and Yeh, 2008; Ariz et al., 2010; Hebbard and George, 2011). This is 
considered as one of the major disadvantages of the mouse model of NAFLD induced by 
these diets (Larter and Yeh, 2008; Ariz et al., 2010; Hebbard and George, 2011). A 
significant increase, 1.5–3-fold, in relative liver weight was observed in six of the seven 
strains fed the CFD diet (Table 1).
Serum triglycerides, cholesterol, and glucose levels were affected by the methyl donor-
deficient diet in a strain-dependent manner (Table 1). A decrease in triglycerides was 
significant in five of the seven strains tested and a greater than 50% reduction was observed 
in CAST/EiJ mice. The magnitude of change in serum cholesterol and glucose levels was 
less pronounced. Only two strains, PWK/PhJ, and WSB/EiJ, exhibited a greater than 50% 
significant reduction in cholesterol and a significant decrease in serum glucose 
concentrations was found in WSB/EiJ mice only.
Feeding the CFD diet resulted in a significant increase in the activity of serum enzyme 
markers of liver injury, ALT and AST, in C57BL/6J, C3H/HeJ, CAST/EiJ, PWK/PhJ, and 
WSB/EiJ strains (Table 1), which was significantly correlated with the degree of liver injury 
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(Supplementary Figure 1). Serum activity of LDH was increased significantly in CAST/EiJ, 
PWK/PhJ, and WSB/EiJ strains by 1.9, 2.4, and 2.6-fold, respectively.
Histopathological evaluation of liver injury revealed the presence of NAFLD-associated 
pathomorphological features, including cytoplasmic alteration, steatosis, necrosis, 
inflammation, oval cell hyperplasia, and karyomegaly in all mice fed the CFD diet (Table 2). 
Interestingly, the magnitude of the liver injury varied greatly among strains with the extent 
of total liver injury increasing in the following order according to the total liver pathology 
scores: A/J ≈ C57BL/6J ≈ C3H/HeJ < 129S1/SvImJ ≈ CAST/EiJ < PWK/PhJ < WSB/EiJ. 
Lipid accumulation in hepatocytes was characterized by microvesicular, macrovesicular, and 
most commonly mixed (microvesicular and macrovesicular) patterns of fat deposition. 
Hepatocytes with microvesicular fat accumulation appeared foamy, with the cytoplasm 
partially or completely filled with numerous small lipid vacuoles, which did not displace the 
nucleus to the periphery. This pattern of steatosis was most pronounced in A/J mice (Figure 
1C). Macrovesicular fatty change was morphologically characterized by hepatocytes mostly 
containing a moderately large to large and well-defined single rounded vacuole within each 
cell. The nucleus and cytoplasm were displaced to the periphery in such cells. This pattern 
was commonly observed in strains exhibiting the greatest degree of liver injury, such as 
WSB/EiJ mice (Figure 1D).
Inflammatory foci (Figures 1C and 1D, marked by arrowheads) were composed of a mixed 
population of polymorphonuclear and mononuclear cells, mainly neutrophils, macrophages, 
and lymphocytes. Single-cell necrosis was one of the most common histopathological 
observations in both of the PWK/PhJ and WSB/EiJ mouse strains, but was most severe in 
the WSB/EiJ mice. Karyomegaly, characterized as 2–4 times larger than typical hepatocyte 
nuclei, was found in CFD diet-fed mice from PWK/PhJ and WSB/EiJ strains (Figure 1; 
compare larger sized nuclei in Figures 1C and 1D). Hyperplasia of oval cells, stem cells of 
bile ductular epithelium that appeared as single or double rows of oval- or round-shaped 
cells organized in linear arrays in liver sinusoids, was also observed in choline- and folate- 
deficient PWK/PhJ and WSB/EiJ mice.
Effect of a choline- and folate-deficient diet on hepatic microRNA expression profile
Dysregulation of hepatic expression of miR-34a, miR-122, miR-181a, miR-192, miR-200b, 
and miR-221 was previously reported to be a common feature in human (Cheung et al., 
2008) and mouse NAFLD (Wang et al., 2009a; Pogribny et al., 2010). Because an inter-
strain difference in liver injury phenotype elicited by the CFD diet was observed in this 
study, we investigated whether or not hepatic expression of these miRNAs may reflect 
variability in the degree of NAFLD or may be associated with strain-specific susceptibility 
to liver injury. The expression of miR-122 was down-regulated by 25 to 60% in the livers of 
A/J, C57BL/6J, PWK/PhJ, and WSB/EiJ mice fed the CFD diet (Figure 2). No change was 
observed in C3H/HeJ, 129S1/SvlmJ, or CAST/EiJ mice. MiR-192 was down-regulated by 
50% only in C57BL/6J mice and slightly up-regulated in CAST/EiJ mice.
The expression of miR-34a, miR-200b, and miR-181a was significantly increased in CFD 
diet-fed mice of a majority of strains in a strain-dependent manner, with the maximum 
response occurring in WSB/EiJ mice (Figure 2). Up-regulation of hepatic expression of 
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miR-221 was most pronounced (>10-fold) in PWK/PhJ mice, with a smaller, but significant, 
increases being observed in C3H/HeJ, 129S1/SvlmJ, CAST/EiJ, and WSB/EiJ mice. In 
contrast, feeding the CFD diet did not affect the expression of a ubiquitous non-liver-
specific miRNA let-7c in all but WSB/EiJ mice (Supplementary Figure 2).
Effect of a choline- and folate-deficient diet on plasma microRNA expression profile
Plasma levels of miRNAs have been shown to be correlated with the degree of liver injury 
in response to drug treatment (Wang et al., 2009b; Larerza et al., 2009). We evaluated the 
differences in patterns of miRNA changes in plasma of mice fed control or CFD diet. Figure 
3 demonstrates that there were strain-specific differences in the levels of miRNAs in the 
mice fed the CFD diet. Notably, in A/J mice, one of the strains with the lowest extent of 
methyl donor-deficient diet-induced liver injury, none of the miRNAs was increased by 
feeding the CFD diet. In contrast, in plasma of PWK/PhJ and WSB/EiJ mice, strains that 
exhibited the greatest degree of liver injury, each of miRNAs, with the exception of 
miR-200b was significantly increased by choline and folate deficiency.
Because strain-dependent effects of treatment on miRNA levels in liver and plasma were 
observed, we tested whether the inter-strain difference in the degree of liver injury 
correlated with miRNA expression. Figure 4 shows that the induction of miR-34a, 
miR-181a, miR-200b and miR-221 in the livers is significantly correlated with the 
histopathology score in CFD diet-fed mice, with the strongest correlations being observed 
with miR-181a and miR-200b. Interestingly, expression of miR-122 and miR-192 in the 
livers, two of the most abundant hepatic miRNAs (Gatti et al., 2011), did not correlate with 
the extent of liver injury.
Figure 5 shows that plasma levels of each of the miRNAs were significantly correlated with 
the degree of liver injury induced by the CFD diet, with strongest correlation occurring with 
miR-34a, whereas level of circulating miRNA let-7c did not differ (Supplementary Figure 
2).
DISCUSSION
The results of the present study demonstrate that feeding a multistrain panel of inbred mice 
the CFD diet for 12 weeks resulted in strain-specific changes in biochemical indicators of 
liver injury in plasma (Table 1) and accumulation of microscopically observed lesions in the 
livers similar to human NAFLD (Table 2, Figure 1). The previous comprehensive studies 
have established that dietary-based models of NAFLD induced by methionine- and choline-
deficient or choline-deficient diets are the best models to study mechanisms of liver injury in 
NAFLD, despite the fact that some of the features do not resemble pathogenesis of NAFLD 
in humans (Larter and Yeh, 2008; Ariz et al., 2010; Hebbard and George, 2011; Maher, 
2011). One of the major disadvantage of the mouse NAFLD model induced by methionine- 
and choline-deficient or choline-deficient diets is associated with significant loss of body 
weight (Larter and Yeh, 2008; Ariz et al., 2010; Hebbard and George, 2011). The results of 
the present study showing that feeding the methionine-containing CFD diet induced liver 
injury without the loss of body weight, overcome this shortcoming of the commonly used 
methionine- and choline-deficient or choline-deficient diets.
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The magnitude of biochemical indicators of liver injury in plasma and the extent of 
histomorphological changes in the livers ranged, with the order being: A/J ≈ C57BL/6J ≈ 
C3H/HeJ < 129S1/SvImJ ≈ CAST/EiJ < PWK/PhJ < WSB/EiJ. More importantly, the 
pathomorphological alterations in the livers were accompanied by different expression 
patterns of hepatic miR-122, miR-181a, miR-192, miR-34a, miR-200b, and miR-221.
miRNA-122 is the most abundant and highly liver-specific miRNA, accounting for 70% of 
all miRNAs in the adult liver (Girard et al., 2008; Lewis and Jopling, 2010). The expression 
of hepatic miR-122 has been reported to decrease significantly in individuals with viral- and 
alcohol-induced liver injuries and NASH (Cheung et al., 2008; Morita et al., 2011) and to be 
inversely correlated with the severity of liver histopathology. Similar down-regulation of 
miR-122 has been reported in experimental animals with NAFLD (Wang et al., 2008b; 
Pogribny et al., 2010). However, the results of present study demonstrate clearly the 
existence of inter-strain variability in expression of hepatic miR-122 in response to feeding 
the CFD diet. Specifically, down-regulation of miR-122 was found only in the livers of A/J, 
C57BL/6J, PWK/PhJ, and WSB/EiJ mice only. More importantly, while changes in 
miR-122 expression in the livers may be reflective of liver injury, the down-regulation of 
this miRNA was not associated with severity of liver injury. This was evidenced by the fact 
that changes in hepatic miR-122 expression did not correlate with the magnitude of 
pathomorphological changes in the livers of choline- and folate-deficient mice (Figure 4). 
Likewise, the expression of another highly abundant and liver-specific miRNAs, miR-192, 
was not associated with the severity of liver damage induced by a CFD diet. In contrast, 
expression of miR-34a, miR-200b, miR-221 and miR-181a miRNAs increased across 
strains, with the greatest magnitude being found in sensitive PWK/PhJ, and WSB/EiJ 
strains. More importantly, up-regulation of miR-34a, miR-181a, miR-200b, and miR-221 in 
the livers of CFD diet-fed mice strongly correlated with a severity of NAFLD-related 
pathomorphological changes in the livers.
The most notable finding in this study is that plasma levels of each of the miRNAs were 
significantly correlated with the severity of liver injury induced by the CFD diet, with 
strongest correlation occurring with miR-34a.
It has been suggested that plasma miRNAs may be potential biomarkers to diagnose and 
monitor diseases (Cortez and Calin, 2009), including several types of liver pathologies, 
ranging from drug-induced liver injury to chronic viral hepatitis and NAFLD (Wang et al., 
2008b; Laterza et al., 2009; Bihrer et al., 2011; Cermelli et al., 2011). Specifically, the 
increased levels of plasma miR-122 alone or the combination of miR-122 and miR-192 have 
been used to detect liver injury induced by traditional liver toxicants, including 
trichlorobromomethane, carbon tetrachloride, and acetaminophen in rats and mice (Wang et 
al., 2008b; Laterza et al., 2009). Importantly, several recent clinical studies have 
demonstrated that the levels of circulating miR-122, miR-192, and miR-34a are significantly 
higher in patients with acetoaminophen-induced acute liver injury, NAFLD, and chronic 
hepatitis C infection suggesting that plasma miRNAs may be useful biomarkers to monitor 
ongoing damage of hepatocytes and the magnitude of necroinflammation (Cermelii et al., 
2011; Starkey Lewis et al., 2011). The results of the present study showing a high and 
significant correlation between the levels of miR-122, miR-181a, miR-192, miR-34a, 
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miR-200b, and miR-221 in plasma and a severity of NAFLD-specific pathomorphological 
changes in the livers of mice fed the CFD diet reinforce this suggestion. More importantly, 
the lack of changes in the plasma level of ubiquitous non-liver-specific miRNA let-7c 
indicates that these circulating miRNAs may be potential liver-specific biomarkers for 
noninvasive evaluation of liver injury in NAFLD. In addition, a strong correspondence 
between correlation of the levels on miRNAs and the activity of ALT and AST in plasma 
with the extent of liver injury suggests that miRNAs may serve as independent robust 
biomarkers of liver injury (Figure 5 and Supplementary Figure 1).
In conclusion, the results of our study demonstrate that development of NAFLD in mice 
induced by a choline- and folate-deficient diet is associated with altered expression of 
hepatic miRNAs and their subsequent elevation in plasma. More importantly, the severity of 
NAFLD is strongly associated with levels of circulating miR-122, miR-181a, miR-192, 
miR-34a, miR-200b, and miR-221 that mirror the magnitude of NAFLD-associated liver 
injury. These results suggest that circulating miRNAs may be applied in human population-
based studies as sensitive genetic background-independent indicators for noninvasive 
monitoring the development and extent of NAFLD-associated liver injury. Additionally, 
they can be used as potential noninvasive indicators of susceptibility to NAFLD liver injury.
Supplementary Material






NAFLD nonalcoholic fatty liver disease
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Figure 1. Representative hematoxylin and eosin staining of liver tissues from control A/J and 
WSB/EiJ mice (A,B) mice fed the choline- and folate-deficient diet (C,D)
(A) Representative liver section from control A/J mice. (B) Representative liver section 
from control WSB/EiJ mice. (C) Representative liver section from A/J mice fed the CFD 
diet for 12 weeks. Minimal steatosis and inflammation (arrows) in the livers. (D) 
Representative liver section from WSB/EiJ mice fed the CFD for 12 weeks. Severe steatosis, 
inflammation (arrowheads) and necrosis (arrows) of hepatocytes in the livers.
Tryndyak et al. Page 12






















Figure 2. Expression changes of miR-122, miR-34a, miR-200b, miR-192, miR-221, and miR-181a 
miRNAs in the livers of control mice and mice fed the choline- and folate-deficient diet
The miRNA expression data are presented as fold change of each miRNA normalized to that 
of snoRNA202 in the livers of mice fed the CFD diet compared to control mice (n = 5, mean 
± SED). Gray bars – control groups; black bars – CFD diet groups.
* - Significantly different from age-matched control mice.
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Figure 3. Levels of miR-122, miR-34a, miR-200b, miR-192, miR-221, and miR-181a miRNAs in 
plasma of control mice and mice fed the choline- and folate-deficient diet
The miRNA expression data are presented as fold change of each miRNA normalized to that 
of normalized to mmu-miR-16, a ubiquitous non-liver-specific miRNA in plasma of mice 
fed the CFD diet compared to control mice. (n = 5, mean ± SED). Gray bars – control 
groups; black bars – CFD diet groups.
* - Significantly different from age-matched control mice.
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Figure 4. Correlation plots of total liver pathology scores and induction of miRNAs in the livers 
of mice fed the choline- and folate-deficient diet
Total liver pathology scores represent the mean severity for all of the lesions detected in the 
liver of mouse. Each symbol represents individual animal in the CFD diet group in respected 
mouse strain.
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Figure 5. Correlation plots of total liver pathology scores and induction of miRNA levels in 
plasma of mice fed the choline- and folate-deficient diet
Total liver pathology scores represent the mean severity for all of the lesions detected in the 
liver of mouse. Each symbol represents individual animal in the CFD diet group in respected 
mouse strain.
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